

S20-4 **“operational guideline of pharmacogenomics testing” and protection of personal genetic information**

○Masayoshi TSUTSUMI¹

¹SRL, Inc. Academic & Scientific Information Group Information & Planning Department

In order to apply study of genome/gene analysis into personalized genomic medical care, pharmacogenomics testing (PGx testing), which can be helpful to predict effectiveness and side-effects of medication and to figure out dosage, has been paid more attention.

We need to formulate operational guideline of PGx testing on clinical application under this circumstance, and “operational guideline of pharmacogenomics testing” has been declared. This guideline consists of 4 items.

Because genetic testing reveals genetic information, which is constant in life, we need to think carefully about informed consent before the test, protection of personal genetic information, treatment of specimen for the test, developing counseling for taking genetic test, and so on.

Treatment of genetic information in PGx testing, however, should be in a receptive framework rather than the strict framework based on the genetic information exceptionalism in monogenic disease and congenital metabolic disorder.

We also should cooperate between pharmaceutical, genetics and medical test studies in order to promote PGx testing.